Lheureux S, et al. - This study was planned to determine the safety and antitumor activity of ipilimumab in recurrent cervical cancer. In the study population, monotherapy with ipilimumab had minimal clinical activity but increased peripheral lymphocyte activation markers; failure to note these changes in tumors could explain the lack of clinical activity.